-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-06760805 in Streptococcal Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PF-06760805 in Streptococcal InfectionsDrug Details:PF-06760805 is under development for the prevention of invasive group B Streptococcus...
-
Product Insights
New![]()
La Castellana-Central Puerto Wind Farm
La Castellana-Central Puerto Wind Farm is an Onshore Wind project located in Buenos Aires, Argentina. The project is owned by Central Puerto SA; CP Renovables SA and is developed by Central Puerto SA; CP Renovables SA; CPR Energy Solutions SAU. The project is currently partially active. Empower your strategies with our La Castellana-Central Puerto Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OLX-301A in Wet (Neovascular / Exudative) Macular Degeneration
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.OLX-301A in Wet (Neovascular / Exudative) Macular Degeneration Drug Details:OLX-301A is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Adrulipase alfa in Exocrine Pancreatic Insufficiency
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Adrulipase alfa in Exocrine Pancreatic InsufficiencyDrug Details:Adrulipase alfa is under development for the treatment of exocrine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OLX-301A in Dry (Atrophic) Macular Degeneration
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.OLX-301A in Dry (Atrophic) Macular DegenerationDrug Details:OLX-301A is under development for the treatment of wet and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OLX-301A in Geographic Atrophy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.OLX-301A in Geographic AtrophyDrug Details:OLX-301A is under development for the treatment of wet and dry macular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Glioblastoma Multiforme (GBM) Drug Details: Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. Keytruda...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Ovarian Cancer Drug Details: Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. Keytruda is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Metastatic Adenocarcinoma of The Pancreas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Metastatic Adenocarcinoma of The Pancreas Drug Details: Pembrolizumab (Keytruda) is an antineoplastic immunomodulating...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drug Details: Pembrolizumab (Keytruda) is an...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.